Patients in the Gill Center’s Neurofbromatosis Program have access to the country’s leading NF research. Our program was one of five nationally to participate in a clinical trial to determine the effectiveness of GLEEVEC (imatinib mesylate) to treat plexiform neurofbromas – disfguring, painful congenital lesions associated with NF1 that can result in substantial morbidity and early mortality. The trial, which closed in 2012, concluded that the drug demonstrated potential to inhibit plexiform neurofbromas in the head, neck and pelvis.
Our Neurofibromatosis Program was also selected as a site for a clinical trial to determine whether Lovastatin™ significantly improves visual spatial learning and/or sustained attention in children with NF1 (NCT00853580: A Randomized Placebo- Controlled Study of Lovastatin in Children With Neurofbromatosis Type 1). We are one of only 10 NF programs to participate in the study and the only one in the Southwest